Zobair M. Younossi
Inova Fairfax Hospital
2 papers in the Anchorcite directory, published between 2015 and 2017, cited 18,650 times in total.
ORCID profileResearch topics
- Alcohol Consumption and Health Effects · 2 papers
- Liver Disease Diagnosis and Treatment · 2 papers
- Liver Diseases and Immunity · 2 papers
Frequent co-authors
- Aaron B. Koenig · 1 paper
- Dinan Abdelatif · 1 paper
- Yousef Fazel · 1 paper
- Linda L Henry · 1 paper
- Mark Wymer · 1 paper
- Naga Chalasani · 1 paper
- Joel E. Lavine · 1 paper
- Michael Charlton · 1 paper
Papers
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology · 2015 · 11,172 citations
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology…
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology · 2017 · 7,478 citations
Potential conflict of interest: Dr. Chalasani consults for and received grants from Eli Lilly. He consults for NuSirt, AbbVie, Afimmune, Tobira, Madrigal, Shire, Cempra, Ardelyx, Axovant, and Amarin. He received grants from Intercept, Gilead, Galectin, and Cumberland. Dr. Younossi consults…
Metadata from OpenAlex (CC0).